|By PR Newswire||
|January 15, 2014 08:01 AM EST||
NEW YORK, January 15, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Natus Medical, Inc. (NASDAQ: BABY), Haemonetics Corporation (NYSE: HAE), AngioDynamics, Inc. (NASDAQ: ANGO), Horizon Pharma, Inc. (NASDAQ: HZNP), and ImmunoGen, Inc. (NASDAQ: IMGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Natus Medical, Inc. Research Report
On January 8, 2014, Natus Medical, Inc. (Natus) announced that it will release its Q4 2013 financial results on January 29, 2014, before the market opens. The Company stated that its management will host an investment-community conference call on the same day at 8:00 a.m. PT / 11:00 a.m. ET to discuss the results, as well as to answer questions. Natus added that the call can be accessed through its website, where a recording of the call will be available for 90 days after the call concludes. The Full Research Report on Natus Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Haemonetics Corporation Research Report
On January 12, 2014, Haemonetics Corporation (Haemonetics) announced that it has entered into a multi-year agreement with HemeXcel Purchasing Alliance LLC (HemeXcel) to supply HemeXcel with certain whole blood collection components on an exclusive basis during 2014-2016. Brian Concannon, Haemonetics' President and CEO, commented, "We are very pleased with our selection by HemeXcel to meet their needs for whole blood collection products. We appreciate their confidence in our ability to deliver high quality products and services economically." Haemonetics added that the incremental business volume is not expected to have a material impact on its FY 2014 revenue or earnings. According to the Company, the incremental volume will represent approximately five net points of US whole blood disposables share gain in FY 2015 and beyond, considered together with a smaller recent U.S. tender that was not awarded to the Company. Haemonetics informed that a live webcast presentation will be held at 10:00 a.m. PT / 1:00 p.m. ET on January 15, 2014 to comment on this agreement. The Full Research Report on Haemonetics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
AngioDynamics, Inc. Research Report
On January 9, 2014, AngioDynamics, Inc. (AngioDynamics) reported financial results for Q2 FY 2014 (period ended November 30, 2013). In Q2 FY 2014, the Company's net sales increased 1.8% YoY to $88.6 million, while net loss for the quarter was c.$0.1 million, or break-even on a per share basis, compared to net income of c.$2 million, or $0.06 per diluted share, in Q2 FY 2013. Joseph M. DeVivo, President and CEO of AngioDynamics, commented, "AngioDynamics' better than expected sales reflects improved performance in our three businesses - Peripheral Vascular, Vascular Access and Oncology/Surgery - compared to the prior quarter. Our new products, specifically AngioVac, BioFlo PICCs and ports, and the Acculis microwave system, represent disruptive emerging technologies that are contributing to our growth while improving patient outcomes and reducing costs to the healthcare system." Mark Frost, Executive Vice President and CFO, added, "We are anticipating revenue to range from $85 million to $88 million in the fiscal third quarter of 2014, a 4% to 8% increase at the top end compared with the year ago fiscal third quarter. Adjusted EPS, excluding amortization, is expected to be $0.15 to $0.18 per share." The Full Research Report on AngioDynamics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Horizon Pharma, Inc. Research Report
On January 9, 2014, Horizon Pharma, Inc. (Horizon Pharma) announced that the Compensation Committee of the Company's Board of Directors has approved the grant of inducement stock options to purchase an aggregate of 363,900 shares of common stock to 93 new employees, in accordance with the NASDAQ Listing Rule 5635(c)(4). The Company informed that each stock option has an exercise price per share of $8.59, vests over four years, has a ten year term, and is subject to the terms and conditions of the Company's 2011 Equity Incentive Plan and the stock option agreement. The Full Research Report on Horizon Pharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
ImmunoGen, Inc. Research Report
On January 9, 2014, ImmunoGen, Inc. (ImmunoGen) announced a multi-year, strategic collaboration with CytomX Therapeutics (CytomX) to develop Probody-drug conjugate (PDC) therapies for the treatment of cancer. ImmunoGen informed that under the agreement, the Companies will collaborate to develop PDCs against a defined number of targets, bringing together CytomX's proprietary antibody masking technology and tumor-selective protease substrates with ImmunoGen's antibody-drug conjugate (ADC) cell-killing agents and engineered linkers. John Lambert, PhD, Executive Vice President and Chief Scientific Officer of ImmunoGen, commented, "We believe using our state-of-the-art ADC technology with CytomX's highly promising Probody Platform will enable us to develop therapies particularly well-suited for certain challenging cancers." The Full Research Report on ImmunoGen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner